

# FACTSHEET



## Specialty pharma meets M&A competence

CHEPLAPHARM is a family-owned pharmaceutical company, headquartered in Germany. We offer our branded products on a global level.



By focusing on an internationally oriented Buy and Build Strategy, we generate annually increasing growth rates. For 2017, CHEPLAPHARM plans for an annual turnover of more than 235 million EURO (2016: 121 million EURO).

---

*Being a European pharmaceutical company, it is our **vision** to strengthen CHEPLAPHARM's position as global player and to expand our international footprint.*

*It is our **mission** to offer high quality products so that our patients as well as our business partners and employees benefit from our success*

---

## Track-Record

During the past 25 years, the owner family BRAUN successfully concluded more than 80 acquisitions with well-known pharmaceutical companies in more than 120 countries. The total deal value exceeds 800 million EURO.

Our achievements are a solid foundation for our future development.

## International Footprint

CHEPLAPHARM benefits from a growing international presence with a well-established partner network. Therefore, we are operating in more than 120 countries and are holding more than 400 registrations worldwide.

Our subsidiaries are located in strategically selected markets, such as the United States of America and France, both reinforcing our International Footprint.



## How to reach us

### CHEPLAPHARM Arzneimittel GmbH

Headquarter  
Bahnhofstraße 1a  
17498 Mesekenhagen

Office  
Ziegelhof 24  
17489 Greifswald

Tel.: +49 (0) 3834 8539-0  
Fax: +49 (0) 3834 8539-349

Internet: [www.cheplapharm.com](http://www.cheplapharm.com)  
Email: [info\[at\]cheplapharm.com](mailto:info[at]cheplapharm.com)

## Our Portfolio

With a clearly defined focus on selected pharmaceutical brands and niche products we offer a diversified portfolio covering a range of therapeutic areas and indications.

### Primary therapeutic areas:

- Antihypertonica: DILATREND®/CO-DILATREND® and ALDACTONE®
- Antiobesity: XENICAL®
- Gastroenterology: DEURSIL®/URSOLVAN®
- Haematooncology: VESANOID®
- Sleeping disorders: ROHYPNOL®
- Emergency medicine: ANEXATE®
- Addiction medicine: DISTRANEURIN®/HEMINEVRIN®
- Urology: POTABA®

## Sales by Business Segments

Almost 80% of our product portfolio is comprised of branded as well as specialty pharma with unique selling propositions.

## Sales by Geographical Position

CHEPLAPHARM, headquartered in Northern Germany, is characterized by its strong European presence. In 2016, more than three quarters of the company's turnover were generated in Europe. The remaining turnover is divided equally on the Rest of the World.

## CHEPLAPHARM at a Glance

- We consequently pursue a Buy and Build Strategy and benefit from our extensive experience in M&A's and business transfers.
- We market branded niche products globally in more than 120 countries.
- We generate annually increasing growth rates.